How to Buy Syndax Pharmaceuticals Stock
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Syndax Pharmaceuticals stock last closed at $20.37, down 0.2% from the previous day, and has increased 51.22% in one year. It has overperformed other stocks in the Biotechnology industry by 0.96 percentage points. Syndax Pharmaceuticals stock is currently +137.41% from its 52-week low of $8.58, and -4.01% from its 52-week high of $21.22.
At the moment, there are 86.91M SNDX shares outstanding. The market value of SNDX is $1.77B. In the last 24 hours, 1.18M SNDX shares were traded.
How to Buy Syndax Pharmaceuticals Stock
Wondering how to invest in Syndax Pharmaceuticals stock? Here's how.
- Figure out where to buy Syndax Pharmaceuticals stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you choose where to buy Syndax Pharmaceuticals stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit funds into your brokerage account: Pick your payment method and add your information.
- Analyze Syndax Pharmaceuticals stock: The Syndax Pharmaceuticals ticker symbol is SNDX. Is Syndax Pharmaceuticals stock a good investment? Should you buy shares of SNDX? How do SNDX's underlying business fundamentals look? Do top analysts think Syndax Pharmaceuticals is a good buy? Why has SNDX's stock price moved recently? (Hint: Our stock research website can help you figure out if SNDX is a good stock to buy).
- Execute your SNDX buy order: Decide if you will purchase SNDX shares at the current market price or use a limit order to buy SNDX shares at a given price.
- Get the latest news on your SNDX position: Create a watchlist to monitor your new investment in Syndax Pharmaceuticals shares.
Step 1: Figure out where to buy Syndax Pharmaceuticals stock
You need a brokerage account in order to access the NASDAQ market and buy SNDX shares.
Our preferred brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Tech to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the right brokerage, it's time to fill out some personal details so you can buy SNDX stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open your new brokerage account.
- Submit your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have finished signing up on the best stock app, you can securely and quickly fund your account:
Watch this video walkthrough if you need help depositing funds into your brokerage account.
Step 4: Analyze Syndax Pharmaceuticals stock
After you have decided on the best place to buy Syndax Pharmaceuticals stock, it's critical to analyze their stock before you invest, so you actually wrap your head around the risk and upside.
Syndax Pharmaceuticals quick stats
SNDX Fundamentals
WallStreetZen was built to help average investors perform more accurate fundamental analysis quickly.
You can see all of the due diligence checks on SNDX's stock page.
What is the fair value of SNDX stock?
You can use many financial metrics, analyses, models, and charts to gauge SNDX's intrinsic value.
Using relative valuations metrics:
- SNDX may be overvalued based on its P/B ratio of 15.34x, relative to Biotechnology industry P/B ratio of 5.32x
You can do more valuation research on SNDX's stock here.
SNDX Financial Health Overview
Pros:
- SNDX has cash burn of 311011000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the SNDX balance sheet.
- There are more short-term assets than long-term liabilities on the SNDX balance sheet.
Cons:
- SNDX has a relatively high debt to equity ratio of 3.78.
- SNDX has $454.39M in cash and short term investments. This is not sufficient to cover its annual cash burn of $311.01M.
- Total SNDX debt is higher than 5 years ago, relative to shareholder equity.
- SNDX profit margin has gone up by 15.77 percentage points in the past year, but the company is still unprofitable.
Is Syndax Pharmaceuticals stock a Buy, Hold, or Sell, according to analysts?
Out of 9 Equities analysts who track SNDX, the consensus analyst rating on Syndax Pharmaceuticals is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Latest SNDX Analyst Ratings
Andres Y. Maldonado, a top 20% analyst from HC Wainwright & Co. reiterates SNDX with a buy rating and maintains their SNDX price target from $40.00 to $40.00, on Oct 27, 2025.
Bradley Canino, a top 20% analyst from Stifel Nicolaus reinstates SNDX with a strong buy rating and announces their SNDX price target of $44.00, on Sep 10, 2025.
Corinne Johnson, a top 28% analyst from Goldman Sachs maintains SNDX with a strong buy rating and raises their SNDX price target from $20.00 to $24.00, on Sep 5, 2025.
Yigal Nochomovitz, a top 8% analyst from Citigroup maintains SNDX with a strong buy rating and raises their SNDX price target from $46.00 to $51.00, on Aug 5, 2025.
Citigroup's Yigal Nochomovitz raised their price target on Syndax Pharmaceuticals (NASDAQ: SNDX) by 10.9% from $46 to $51 on 2025/08/05. The analyst maintained their Strong Buy rating on the stock.
Syndax Pharmaceuticals reported its Q2 2025 earnings.
Nochomovitz hiked their price target and put a positive "upside catalyst watch" on Syndax in anticipation of the 2025/10 PDUFA deadline in relapsed or refractory NPM1-mutated acute myeloid leukemia.
Commenting on the quarter, the analyst noted that Revuforj and Niktimvo growth accounted for the $38M in revenue that beat Citigroup's estimates by more than 70% and the Visible Alpha consensus by 45%.
Earnings Report
For Q2 2025, Syndax Pharmaceuticals reported:
- Loss per share of $0.83, which beat the Zacks Consensus Estimate of $(1.00) but missed Q2 2024's $(0.80).
- Revenue of 37.96M, which beat the Zacks Consensus Estimate by 30.74% and Q2 2024's $3.5M.
Management guided that "the company's cash, cash equivalents and short- and long-term investments, combined with its anticipated product revenue and interest income, will enable Syndax Pharmaceuticals to reach profitability."
CEO Michael A. Metzger commented: “Syndax reported another remarkable quarter.
"With strong Revuforj and Niktimvo sales momentum along with our expectation for stable expenses over the next few years and more than $500 million in cash, we are well on our way to becoming a profitable company with two blockbuster products.
“Notably, Revuforj net revenue increased 43% quarter-over-quarter, even with approximately a third of patients pausing treatment to receive a stem cell transplant.
"Revuforj is poised for continued growth as we further penetrate the KMT2A population and as patient recontinuations following stem cell transplantation build meaningfully.
"Importantly, we are nearing another major inflection point with the anticipated approval of Revuforj as the first therapy for R/R mNPM1 AML.
"Longer-term, our leadership in the menin space positions us to be first to the frontline and meaningfully expand the franchise.
“Additionally, Niktimvo is off to a very fast start, generating $50 million in net revenue in just the first five months of the launch.
"It is already profitable to Syndax and we expect increasing profitability margins as revenues continue to grow.
"The impressive results demonstrate the benefit of delivering a novel approach to treating chronic GVHD and the potential for Niktimvo to transform patient care and make a substantial financial impact for Syndax.”
You can dive deeper into what analysts are forecasting on the Syndax Pharmaceuticals stock forecast page.
Metrics for Advanced SNDX Traders
SNDX Earnings
Last year, SNDX revenue was $111.55M. During the last 5 year, SNDX's revenue has gone up by 136.24% per year. This was faster than the Biotechnology industry average of 43.8%.
You can analyze SNDX's earnings and revenue performance here.
Latest Insiders Trades at SNDX
Over the past 12 months, executives and large shareholders at SNDX have bought more shares than they have sold.
Michael A. Metzger, Chief Executive Officer of SNDX, was the latest SNDX insider to buy. They bought $1,714,646.30 worth of SNDX stock on Sep 8, 2025.
Research more about who owns SNDX stock here.
Can I rely on SNDX as an income stream?
No, Syndax Pharmaceuticals doesn't provide an income stream by paying out dividends.
What others are saying about SNDX
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your SNDX buy order
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly sufficient. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a given dollar amount limit, use a limit order.
Press the Open Trade button and eToro will execute your order.
If you need additional assistance buying stocks on eToro, watch the how to video below:
Step 6: Get the latest news on your SNDX position
Now that you own some SNDX stock, you'll want to stay up-to-date on your investment.
Make a watchlist to get the latest updates about your SNDX stock.
SNDX Feed
How to Buy Stock in Syndax Pharmaceuticals
To summarize, here are the 6 steps you need to take to buy Syndax Pharmaceuticals stock right now:
- Figure out where to buy Syndax Pharmaceuticals stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Analyze Syndax Pharmaceuticals stock
- Execute your SNDX buy order
- Get the latest news on your SNDX position
If you need a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Syndax Pharmaceuticals, click the button below.
More "How To" Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.